Alexion Ultra-Rare Disease Candidate Makes “Breakthrough” List
Alexion’s asfotase alfa, for treatment of a life-threatening enzyme deficiency disorder, becomes the third rare disease therapy to be awarded FDA’s new breakthrough designation.
Alexion’s asfotase alfa, for treatment of a life-threatening enzyme deficiency disorder, becomes the third rare disease therapy to be awarded FDA’s new breakthrough designation.